An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation

Drug Development and Industrial Pharmacy

Volumn 38, Issue 9, 2012, Pages 1047-1053

  Adidala, Raghuramreddy ^a   Devalapally, Harikrishna ^a   Srivari, Chandrasekhar ^b   Devarakonda, R Krishna ^b   Raghuram Rao, Akkinepally ^a  

^a KAKATIYA UNIVERSITY   (India)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Galactose; Lysosome; Mustard; Prodrug; Solid tumor; Targeted delivery

Indexed keywords

ACROLEIN; AP 5346; BETA GALACTOSIDASE; CAMPTOTHECIN; GALACTOSE; IRINOTECAN; OXALIPLATIN; PACLITAXEL POLIGLUMEX; PEGAMOTECAN; PHOSPHORAMIDIC MUSTARD; PRODRUG; TRETAZICAR; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PROTEIN CLEAVAGE; TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BETA-GALACTOSIDASE; BREAST NEOPLASMS; CELL SURVIVAL; CYCLOPHOSPHAMIDE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; ESCHERICHIA COLI PROTEINS; FEMALE; GALACTOSIDES; HELA CELLS; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; KINETICS; LYSOSOMES; MCF-7 CELLS; PHOSPHORAMIDE MUSTARDS; PRODRUGS;

EID: 84864460291     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.637932     Document Type: Article

References (27)

1. Rang HP, Dale MM, Ritter JM, Moore PK. (2003). Cancer Chemotherapy. Pharmacology. 5th ed. Oxford: Churchill Livingstone, 693-707.
2. Spinger CJ, Duvaz IN. (1995). Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Design, 10:361-372.
3. Chabner BA, Allegra CJ, Curt GA, Calabresi P. (1996). Goodman and Gilman's The pharmacological basis of therapeutics, Antineoplastic agents. New York, U.S.A: McGraw-Hill, 1233-1257.
4. Carl PL, Chakravarty PK, Katzenellenbogen JA. (1981). A novel connector linkage applicable in prodrug design. J Med Chem, 24:479-480.
5. Connors TA. (1978). Antitumour drugs with latent activity. Biochemie, 60:979-987.
6. Bagshawe KD. (1989). The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer, 60:275-281.
7. Senter PD, Springer CJ. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Deliv Rev, 53:247-264.
8. De Groot FM, Damen EW, Scheeren HW. (2001). Anticancer prodrugs for application in monotherapy: Targeting hypoxia, tumorassociated enzymes, and receptors. Curr Med Chem, 8:1093-1122.
9. Springer CJ, Duvaz IN. (1996). Gene-directed enzyme prodrug therapy (GDEPT): Choice of Prodrugs. Adv Drug Delivery Rev, 22:351-364.
10. Harikrishna D, Raghavendra SN, Venkateshwarlu Y, Raghuram Rao A, Rama Krishna D. (2007). β-Galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/ prodrug monotherapy. Arch Pharm Res, 30:723-732.
11. Devalapally H, Rajan KS, Akkinepally RR, Devarakonda RK. (2008). Safety, pharmacokinetics and biodistribution studies of a betagalactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm, 34:789-795.
12. Ghosh AK, Khan S, David F. (1999). A β-galactoside phosphoramide mustard prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Chem Commun, 2527-2528.
13. Ravindranathan KP, Harold JJ. (1990). A simplified one pot preparation of acetobromosugars from reduced sugars. J Carbohydrate Chem, 9:777-781.
14. Bollenback GN, Long JW, Benjamin DG, Lindquist JA. (1955). The synthesis of aryl-d-glucopyranosiduronic acids. J Am Chem Soc, 77, 3310-3315.
15. Leu YL, Chen CS, Wu YJ, Chern JW. (2008). Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J Med Chem, 51:1740-1746.
16. Vogel, Brian SF, Antony JH, Peter WGS, Austin RT. (1989). Vogel's text book of practical organic chemistry. 5th ed. New York: Longman Scientific & technical, 960-975.
17. Ghosh AK, David F. (1997). A methyl glucuronate prodrug of phosphoramidic mustard. Tetrahedron Lett, 38:8795-8798.
18. David NP. (2011). AP5346 (ProLindac™), A DACH platinum polymer conjugate in phase II trials against ovarian cancer. Current Bioactive Compounds, 7:21-26.
19. David AW, Thomas LL. (2005). Foye's Principles of medicinal chemistry, Cancer chemotherapy. 5th ed. India: Lippincott Williams & Wilkins, 924-950.
20. Ghosh AK, Khan S, Maini F, Nelson JA, David F. (2000). A daunorubicin β-galactoside prodrug for use in conjunction with gene directed enzyme prodrug therapy (GDEPT). Tetrahedron Lett, 41: 4871-4874.
21. HariKrishna D, Rao AR, Krishna DR. (2003). Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drug News Perspect, 16:309-318.
22. Boyer MJ, Tannock IF. (1993). Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res, 60:269-291.
23. Singh Y, Palombo M, Sinko PJ. (2008). Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem, 15:1802-1826.
24. Chen Y, Hu L. (2009). Design of anticancer prodrugs for reductive activation. Med Res Rev, 29:29-64.
25. Greenwald RB, Pendri A, Conover CD, Lee C, Choe YH, Gilbert C et al. (1998). Camptothecin-20-PEG ester transport forms: The effect of spacer groups on antitumor activity. Bioorg Med Chem, 6:551-562.
26. Knox RJ, Connors TA. (1997). Prodrugs in Cancer Chemotherapy. Pathol Oncol Res, 3:309-324.
27. Dosio F, Stella B, Arpicco S, Cattel L. (2011). Macromolecules as taxane delivery systems. Expert Opin Drug Deliv, 8:33-55.